MedTrace Logo

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

NCT03943472 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-08-31

No results posted yet for this study

Summary

The goal of this clinical trial is to study the feasibility and efficacy of anti-B-Cell Maturation Antigen (BCMA) expressing T cells in treating patients with multiple myeloma.

Conditions

Interventions

BIOLOGICAL

Anti-BCMA CAR-T cells

Retroviral vector-transduced autologous T cells to express anti-BCMA CAR

DRUG

Fludarabine

30mg/m2/d

DRUG

Cyclophosphamide

300mg/m2/d

DRUG

Immune inhibitors

Immune inhibitors

Sponsors & Collaborators

  • Shanghai Changzheng Hospital

    collaborator OTHER

  • Hrain Biotechnology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-08
Primary Completion
2021-11-30
Completion
2022-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03943472 on ClinicalTrials.gov